K De Beule
Janssen Pharmaceutica
14 Papers
168 Citations
K De Beule is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Itraconazole & Aspergillosis. The author has an hindex of 12, co-authored 14 publications.
Chat about Author
Papers
Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics
TL;DR: The oral solution and intravenous formulations of itraconazole produce consistent plasma concentrations and are ideal for the treatment of systemic fungal infections in a wide range of patient populations, including children and those requiring intensive care.
229
Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B
J. L. Harousseau,A. W. Dekker,A. Stamatoullas-Bastard,A. Fassas,W. Linkesch,J. Gouveia,R. De Bock,M. Rovira,W. Seifert,H. Joosen,M Peeters,K De Beule +11 more
TL;DR: A double-blind, double-placebo, randomized, multicenter trial was performed to compare the efficacy and safety of itraconazole oral solution with amphotericin B capsules for prophylaxis of systemic and superficial fungal infection among immunocompromised patients with hematological malignancy.
160
Intravenous Itraconazole Followed by Oral Itraconazole in the Treatment of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies, Chronic Granulomatous Disease, or AIDS
TL;DR: Overall iv/oral itraconazole was safe and effective in invasive aspergillosis and well tolerated, with no unexpected effects.
158
Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis: a double-blind comparative study
John Stratigos,Chr. Antoniou,A. Katsambas,K. Böhler,P. Fritsch,A. Schmölz,D. Michaelidis,K De Beule +7 more
TL;DR: No significant difference was seen between the two groups when the total scores at week 2 and at week 4 were compared with the initial scores, and the incidence of side effects was comparably low.
65
Oral candidosis: treatment with absorbable and non‐absorbable antifungal agents in children
TL;DR: Oral candidosis in neonates and children is a common infection which occurs often during the first few months after birth, but occasionally also in older children with certain predisposing factors, leading to occasionally fatal Candida sepsis or to widespread chronic mucocutaneous candidosis.
14